Abstract
Basal cell carcinoma is a slow-growing, locally invasive tumor. Locally it can be aggressive, destroy neighboring tissues, cause ulceration and invade deep into cartilage and bone. It is considered a chronic disease because many cases that develop their first basal cell carcinoma will subsequently develop at least one additional tumor, and a group of cases have more than one basal cell carcinoma at the time of diagnosis. HeberFERON is the combination of alpha2b and gamma IFNs with antiproliferative, antiangiogenic and immunomodulatory activity. It is a therapeutic modality used in the treatment of basal cell carcinoma and could have a remote effect on the rest of the tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
